0

The full content of Annals is available to subscribers

Subscribe/Learn More  >
Articles |

Suppression of Subclinical Shedding of Herpes Simplex Virus Type 2 with Acyclovir

Anna Wald, MD, MPH; Judith Zeh, PhD; Gail Barnum, ARNP; L.G. Davis, PhD; and Lawrence Corey, MD
[+] Article and Author Information

From the University of Washington, Seattle, Washington, and Burroughs Wellcome Company, Research Triangle Park, North Carolina. Acknowledgments: The authors thank Drs. Jack Hill and David Koelle for performing acyclovir sensitivity testing on viral isolates. Grant Support: By NIH grant AI-30731 and by Burroughs Wellcome Company. Dr. Wald is a recipient of a postdoctoral research fellowship from the American Social Health Association. Requests for Reprints: Lawrence Corey, MD, University of Washington, Virology Division, Room 9301, 1200 12th Avenue South, Seattle, WA 98144. Current Author Addresses: Dr. Wald: Virology Research Clinic, 1001 Broadway, Suite 320, Seattle, WA 98122.


Copyright ©2004 by the American College of Physicians


Ann Intern Med. 1996;124(1_Part_1):8-15. doi:10.7326/0003-4819-124-1_Part_1-199601010-00002
Text Size: A A A

Objective: To assess the effect of the antiviral drug acyclovir on the frequency of subclinical shedding of herpes simplex virus (HSV) in the genital tract.

Design: A double-blind, placebo-controlled, crossover clinical trial.

Setting: A university-based virology research clinic.

Patients: 34 women with herpes simplex virus type 2 (HSV-2) antibody only and genital herpes of less than 2 years' duration.

Intervention: Participants were randomly assigned to receive either acyclovir, 400 mg twice daily for 70 days, followed by a 14-day washout period, and then placebo for 70 days, or the study medications in the reverse order.

Measurements: Women collected daily genital swabs of the vulvar, cervicovaginal, and perianal areas for HSV culture, maintained a diary of genital lesions, and were examined at the time of recurrences.

Results: In an intent-to-treat analysis of the initial treatment period, 15 of the 17 women who received placebo and 3 of the 17 women who received acyclovir had at least 1 day of subclinical shedding (P < 0.001). Among the participants who received placebo, subclinical shedding occurred on 64 of 928 (6.9%) days compared with 3 of 1057 (0.3%) days among the participants who received acyclovir (P < 0.001). The relative risk for subclinical shedding was 0.09 (95% CI, 0.03 to 0.35) for the women who received acyclovir compared with the women who received placebo. In a paired analysis of 26 women who completed both arms of the study, acyclovir therapy was associated with a decrease in the frequency of subclinical shedding; subclinical shedding occurred on 83 of 1439 (5.8%) days with placebo, and on 6 of 1611 (0.37%) days with acyclovir (P < 0.001)—a 94% reduction. The frequency of subclinical shedding was reduced at all anatomic sites and in all patients.

Conclusions: Daily therapy with oral acyclovir suppresses subclinical shedding of HSV-2 in the genital tract, suggesting that studies to evaluate the use of acyclovir in preventing HSV-2 transmission are warranted.

Figures

Grahic Jump Location
Figure 1.
Time to first subclinical shedding of HSV among 34 women during the initial arm of the study.
Grahic Jump Location
Grahic Jump Location
Figure 2.
Comparison of number of days during which lesions were noted among 26 women while they were receiving placebo and acyclovir therapy.
Grahic Jump Location
Grahic Jump Location
Figure 3.
Comparison of total herpes simplex virus shedding rates among 26 women while they were receiving placebo and acyclovir therapy.
Grahic Jump Location

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Articles
Related Point of Care
Topic Collections
PubMed Articles
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)